Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery

Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery is a phase 2, randomised interventional study registered as NCT05296681 by Howard S. Hochster, MD, with a registry enrolment figure of 42 participants, started 2022-05-03 and due to reach its primary completion in 2026-12. Interventions recorded: NBT-NM108. Conditions listed: Metastatic Colon Carcinoma; Stage IV Colon Cancer AJCC v8; Stage IVA Colon Cancer AJCC v8; Stage IVB Colon Cancer AJCC v8; Stage IVC Colon Cancer AJCC v8. Primary outcome: The number of participants with treatment-related Adverse Events as Assessed by Cancer Therapy Evaluation Program Common Toxicity Criteria (CTCAE) Version 5.0 for toxicity and Adverse Event reporting; Tumor Response by RECIST v1.1 Criteria. Colorectal eligibility wording from the registry: "* Biopsy proven and metastatic colon cancer". Sites: United States. No results are recorded here; the registry entry is the source.